Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Zhengzhou
Clinical trial register · China

Clinical Trials in Zhengzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Zhengzhou 75 Henan 4 Luoyang 2 Xinxiang 1 Anyang 1
Narrow the registerReset
Recruitment status
Phase
Site location
Zhengzhou75 Henan4 Luoyang2 Xinxiang1 Anyang1
All 6 locations
Target enrolment
to

Trials with a site in Zhengzhou

75 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Henan Cancer Hospital
Phase 2
155
Zhengzhou
2026-11-01
Not yet open
Henan Cancer Hospital
Observational
147
Zhengzhou
2026-10
Not yet open
Henan Cancer Hospital
Phase 2
75
Zhengzhou
2026-07-10
Not yet open
Henan Cancer Hospital
Phase 2
45
Zhengzhou
2026-06-30
Recruiting
Henan Cancer Hospital
Phase 3
1,044
Zhengzhou
2026-06-16
Not yet open
Henan Cancer Hospital
Observational
20
Zhengzhou
2026-03-10
Recruiting
Henan Cancer Hospital
Phase 2
92
Zhengzhou
2026-01-20
Recruiting
Henan Cancer Hospital
Observational
30
Zhengzhou
2025-11-18
Recruiting
Henan Cancer Hospital
Phase 2
30
Zhengzhou
2025-10-14
Recruiting
QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer
NCT06967103Breast Cancer, HR+/HER2- Breast Cancer
Henan Cancer Hospital
Phase 2
238
Zhengzhou
2025-09-08
Recruiting
Henan Cancer Hospital
Phase 1/2
14
Zhengzhou
2025-09-08
Not yet open
Henan Cancer Hospital
Phase 2
280
Zhengzhou
2025-09-01
Recruiting
Henan Cancer Hospital
Phase 2
224
Zhengzhou
2025-08-30
Recruiting
Henan Cancer Hospital
Phase 1/2
42
Zhengzhou
2025-06-25
Recruiting
Henan Cancer Hospital
Phase 3
812
Zhengzhou
2025-06-24
Recruiting
ARX788 in HER2-positive Metastatic Breast Cancer Patients
NCT06663748HER2-positive, Metastatic Breast Cancer
DrugARX788
Henan Cancer Hospital
Phase 2
44
Zhengzhou
2025-06-16
Not yet open
Henan Cancer Hospital
Phase 1/2
32
Zhengzhou
2025-05-01
Not yet open
Henan Cancer Hospital
Not applicable
124
Zhengzhou
2025-05
Recruiting
Henan Cancer Hospital
Phase 2
180
Zhengzhou
2025-04-16
Recruiting
Henan Cancer Hospital
Phase 2
357
Zhengzhou
2025-04-15
Not yet open
Henan Cancer Hospital
Phase 4
203
Zhengzhou
2025-04
Recruiting
Henan Cancer Hospital
Observational
20
Zhengzhou
2025-02-21
Recruiting
Henan Cancer Hospital
Observational
40
Zhengzhou
2025-02-20
Not yet open
Henan Cancer Hospital
Observational
55
Zhengzhou
2025-02-01
Not yet open
Henan Cancer Hospital
Phase 2
250
Luoyang, Xinxiang, Zhengzhou
2025-01-15
Recruiting
Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN
NCT07187908Primary/Secondary Prevention, High Risk for Febrile Neutropenia of Chemotherapy Regimens, Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia
Henan Cancer Hospital
Phase 2
1,076
Zhengzhou
2025-01-01
Not yet open
Henan Cancer Hospital
Observational
100
Zhengzhou
2024-12-30
Not yet open
Henan Cancer Hospital
Observational
80
Zhengzhou
2024-12-28
Not yet open
Application of Antiosteoporosis Therapy in Osteolysis
NCT05617846Limb; Fusion, Complication
Henan Cancer Hospital
Observational
100
Zhengzhou
2024-12-28
Recruiting
Henan Cancer Hospital
Observational
709
Zhengzhou
2024-12-04
Recruiting
Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
NCT06817525Triple-negative Breast Cancer
Henan Cancer Hospital
Phase 2
64
Zhengzhou
2024-11-06
Not yet open
Henan Cancer Hospital
Phase 1
30
Zhengzhou
2024-08-01
Not yet open
Henan Cancer Hospital
Phase 2
46
Zhengzhou
2024-08
Recruiting
Henan Cancer Hospital
Phase 2
48
Zhengzhou
2024-06-19
Not yet open
Henan Cancer Hospital
Phase 2
30
Zhengzhou
2024-06
By invitation
Henan Cancer Hospital
Phase 2
41
Zhengzhou
2024-04-02
Recruiting
Henan Cancer Hospital
Phase 2
63
Zhengzhou
2024-04-01
Recruiting
Henan Cancer Hospital
Phase 1
30
Zhengzhou
2024-03-01
Recruiting
Henan Cancer Hospital
Phase 1/2
70
Zhengzhou
2024-02-28
Recruiting
Henan Cancer Hospital
Phase 2
224
Zhengzhou
2024-02-23
Recruiting
Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
NCT07334431Gastric Adenocarcinoma, Gastric (Stomach) Cancer, GEJ Adenocarcinoma, HER2-positive Gastric Cancer
DrugXelox
Henan Cancer Hospital
Phase 1/2
45
Zhengzhou
2024-02-22
Not yet open
Henan Cancer Hospital
Phase 2
48
Zhengzhou, Wuhan
2024-02-10
Recruiting
Henan Cancer Hospital
Not applicable
22
Zhengzhou
2024-01-15
Recruiting
Henan Cancer Hospital
Phase 1
20
Zhengzhou
2023-11-21
Recruiting
Henan Cancer Hospital
Phase 2
69
Zhengzhou
2023-09-12
Recruiting
The Maintenance Treatment of "ITIVA" in AML Patients
NCT06256627Acute Myeloid Leukemia, Maintenance Treatment, Minor Residue Disease, Interferon-α-1b
Henan Cancer Hospital
Not applicable
130
Zhengzhou
2023-07-11
Recruiting
Henan Cancer Hospital
Phase 2
66
Zhengzhou
2023-07-05
Recruiting
Henan Cancer Hospital
Observational
200
Zhengzhou
2023-05-20
Recruiting
Henan Cancer Hospital
Phase 2
610
Zhengzhou
2023-05-03
Recruiting
Lenvatinib for Advanced Bone and Soft Tissue Sarcoma
NCT05617859Effectiveness, Sexuality
Henan Cancer Hospital
Phase 2
60
Zhengzhou
2023-04-30
Recruiting
Henan Cancer Hospital
Observational
300
Zhengzhou
2023-04-04
Recruiting
Henan Cancer Hospital
Phase 2
150
Zhengzhou
2023-03-31
Recruiting
Henan Cancer Hospital
Phase 2
79
Zhengzhou
2022-08-19
Recruiting
Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors
NCT05468970Bone and Soft Tissue Tumors, Clinical Features
Henan Cancer Hospital
Observational
6,000
Zhengzhou
2022-08-03
Recruiting
Henan Cancer Hospital
Phase 3
219
Zhengzhou
2022-08-01
Recruiting
Henan Cancer Hospital
Phase 2
43
Zhengzhou
2022-07-26
Active, closed
Henan Cancer Hospital
Phase 2
42
Zhengzhou
2022-05-13
Recruiting
Henan Cancer Hospital
Phase 2
134
Zhengzhou
2022-03-22
Recruiting
Henan Cancer Hospital
Phase 2
30
Zhengzhou
2021-12-21
Recruiting
Henan Cancer Hospital
Phase 3
1,979
Zhengzhou
2021-09-28
Recruiting
Toripalimab Plus FLOT in Locally Advanced Gastric Cancer
NCT04891016Chemotherapy, Immune Checkpoint Inhibitor, Locally Advanced Gastric Carcinoma
Henan Cancer Hospital
Phase 2
60
Zhengzhou
2021-06-25
Recruiting
Henan Cancer Hospital
Phase 2
30
Zhengzhou
2021-01-13
Recruiting
Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
NCT04280822Esophageal Cancer, Surgery, Neoadjuvant Treatment, Survival
Henan Cancer Hospital
Phase 3
400
Zhengzhou
2020-04-21
Recruiting
Henan Cancer Hospital
Phase 3
456
Zhengzhou
2019-10-22
Active, closed
Henan Cancer Hospital
Phase 2
60
Anyang, Luoyang, Zhengzhou
2019-08-26
Recruiting
Henan Cancer Hospital
Observational
200
Zhengzhou
2019-01-03
Rows per page Showing 1–75 of 75
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/zhengzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 75 of those studies with a site in Zhengzhou that also match the filters currently applied.

How many clinical trials are recruiting in Zhengzhou?

49 of the 75 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 20 have not yet opened recruitment, 5 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Zhengzhou), 75 studies
PhaseStudiesRecruitingShare
Phase 2422656%
Observational14818.7%
Phase 3668%
Phase 1/2546.7%
Not applicable435.3%
Phase 1324%
Phase 4101.3%

Most active sponsors

Lead sponsors with the most studies (Zhengzhou)
Lead sponsorStudiesRecruiting
Henan Cancer Hospital7549
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.